Cabozantinib Approved for NETs in Scotland | Glasgow News

Big news for Scotland’s NETs patients: the NHS has approved cabozantinib (Cabometyx) as a new oral treatment for advanced neuroendocrine tumors, offering renewed hope and better quality of life for those with limited options. Listen in comfort:Get a discount on a Soli Pillow: http://solipillow.com/discount/dnn. Advertise on DNN:[email protected] This is an automated, high-level news summary based on public reporting.Report issues to [email protected]. View sources & latest updates:https://sources.thednn.ai/d0218ef646452969